相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study
Tomoki Nakamura et al.
CANCER (2016)
A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib
Ting Li et al.
INVESTIGATIONAL NEW DRUGS (2016)
Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
Robert Nakayama et al.
ONCOTARGET (2016)
Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases
William L. Read et al.
CASE REPORTS IN ONCOLOGY (2016)
Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: A new treatment for metastatic soft tissue sarcoma
Girolamo Ranieri et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Extended Progression-Free Survival in Two Patients With Alveolar Soft Part Sarcoma Exposed to Tivantinib
John M. Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
Ryohei Katayama et al.
CANCER RESEARCH (2013)
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
Cristina Basilico et al.
CLINICAL CANCER RESEARCH (2013)
Cediranib for Metastatic Alveolar Soft Part Sarcoma
Shivaani Kummar et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein
Rachel Kobos et al.
JOURNAL OF PATHOLOGY (2013)
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
John C. Araujo et al.
LANCET ONCOLOGY (2013)
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors
Andrew J. Wagner et al.
CANCER (2012)
Bioinformatic Analysis of Patient-Derived ASPS Gene Expressions and ASPL-TFE3 Fusion Transcript Levels Identify Potential Therapeutic Targets
David G. Covell et al.
PLOS ONE (2012)
Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect
S. Stacchiotti et al.
ANNALS OF ONCOLOGY (2011)
VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
Weon-Kyoo You et al.
CANCER RESEARCH (2011)
ASPS-1, A Novel Cell Line Manifesting Key Features of Alveolar Soft Part Sarcoma
Susan Kenney et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Alveolar Soft Part Sarcoma: Clinical Presentation, Treatment, and Outcome in a Series of 33 Patients at a Single Institution
Elisabetta Pennacchioli et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Cellular processes of v-Src transformation revealed by gene profiling of primary cells - Implications for human cancer
Bart M. Maslikowski et al.
BMC CANCER (2010)
ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
Neru Munshi et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Expression of MET in alveolar soft part sarcoma
Hyun Jung Jun et al.
MEDICAL ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Gene expression profiling of alveolar soft-part sarcoma (ASPS)
Luke H. Stockwin et al.
BMC CANCER (2009)
Molecular analyses of cell origin and detection of circulating tumor cells in the peripheral blood in alveolar soft part sarcoma
Makiko Hoshino et al.
CANCER GENETICS AND CYTOGENETICS (2009)
Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma
Silvia Stacchiotti et al.
CLINICAL CANCER RESEARCH (2009)
Tyrosine-phosphorylation: thirty years and counting
Tony Hunter
CURRENT OPINION IN CELL BIOLOGY (2009)
Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray
Alexander J. Lazar et al.
HISTOPATHOLOGY (2009)
Angiogenesis-promoting gene patterns in alveolar soft part sarcoma
Alexander J. F. Lazar et al.
CLINICAL CANCER RESEARCH (2007)
TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition
Masumi Tsuda et al.
CANCER RESEARCH (2007)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Alveolar soft part sarcoma in Japan: Multi-institutional study of 57 patients from the Japanese musculoskeletal oncology group
A Ogose et al.
ONCOLOGY (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25
M Ladanyi et al.
ONCOGENE (2001)
The protein tyrosine kinase family of the human genome
DR Robinson et al.
ONCOGENE (2000)
Alveolar soft part sarcoma in children and adolescents: A report from the Soft-Tissue Sarcoma Italian Cooperative Group
M Casanova et al.
ANNALS OF ONCOLOGY (2000)
分享论文
